Botanix Capital Raising to Extinguish Milestone & Royalty
Filed with ASX · · 5 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call• Botanix has received firm commitments for A$12.5 million via an institutional placement • Proceeds expected to be primarily used to extinguish the future milestone and royalty payments due to Fresh Track Therapeutics Inc in respect of Sofpironium Bromide • A number of new institutional investors with life sciences expertise have committed under the placement, which was led and supported largely
Botanix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Botanix Pharmaceuticals
- Botanix Pharmaceuticals: The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement
- New Territory Licensed for Sofpironium Bromide with Kaken
- March 2023 Quarterly Activities Report and Appendix 4C
- Botanix successfully completes A$10m Placement
- Botanix Raises A$10 million via Institutional Placement
Later from Botanix Pharmaceuticals
- Botanix Closes Capital Raising and Royalty Milestone Buyout
- June 2023 Quarterly Activities Report and Appendix 4C
- Appointment of Dr Howie McKibbon as CEO
- Appendix 4E Preliminary Final Report
- Response to ASX Price and Volume Query
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals